Earnings ·
AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026
ANABAnaptysbio, Inc
AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026. The company posted net income from continuing operations of $177.3 million ($6.06 per share) for Q2 and $176.4 million ($6.09 per share) for the six-month period, driven by a $181.5 million tax benefit following the separation from First Tracks Biotherapeutics. Collaboration revenue reached $27.5 million in Q2 and $53.0 million year-to-date, reflecting 25% and 34% growth in Jemperli royalties respectively. Cash reserves stood at $164.1 million as of June 30. The company highlighted positive interim data from the AZUR-1 trial for dostarlimab, with an FDA PDUFA date set for February 2027, and anticipates a judgment in its litigation with GSK and Tesaro by Q4 2026 or Q1 2027. AnaptysBio operates as a biotechnology company focused on managing financial collaborations for licensed oncology and immunology assets.